New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 1, 2007, Pages 42-50

  García Garayoa, Elisa ^a   Schweinsberg, C ^a   Maes, V ^b   Ruegg D ^a   Blanc, A ^a   Blauenstein P ^a   Tourwe D A ^b   Beck Sickinger, A G ^c   Schubiger, P A ^a  

^a ETH Zurich   (Switzerland)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Bombesin; Neoplasms; Receptors; Technetium

Indexed keywords

BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; BOMBESIN TC 99M; CHELATING AGENT; GASTRIN RELEASING PEPTIDE RECEPTOR; UNCLASSIFIED DRUG; BOMBESIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DRUG DISTRIBUTION; DRUG STABILITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS; PROSTATE TUMOR; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN TRANSPORT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ADENOCARCINOMA; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DRUG DELIVERY SYSTEM; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; BOMBESIN; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 34249684449     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971-94.
2. Signore A, Annovazzi A, Chianelli M, Corsetti F, van de Wiele C, Watherhouse RN et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001;28:1555-65.
3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev 2003;24:389-427.
4. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancer and other diseases. Med Res Rev 2004;24:357-97.
5. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors: an overview of European results. Ann N Y Acad Sci 1994;733:416-24.
6. Leners N, Jamar F, Fiasse R, Ferrant R, Pauwels S. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma. J Nucl Med 1996;37:916-22.
7. Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A et al. Use of the somatostatin analogue octreotide to localize and manage somatostatin-producing tumours. Gut 1998;42:792-4.
8. van Eijck CH, Kwekkeboom DJ, Krenning EP. Somatostatin receptors and breast cancer. Q J Nucl Med 1998;42:18-25.
9. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med 2000;41:107-10.
10. García-Garayoa E, Maes V, Bläuenstein P, Blanc A, Hohn A, Tourwé D et al. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NT receptor-positive tumors. Nucl Med Biol 2006;33:495-503.
11. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:247-58.
12. 1]-minigastrin. Bioconjugate Chem 2004;15:864-71.
13. 13]bombesin in the frog Bombina orientalis. J Biol Chem 1996;271:7731-7.
14. Spindel ER, Giladi E, Brehm P, Goodman RH, Segerson TP. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol 1990;4:1956-63.
15. Wada E, Way J, Shapira H, Kusano K, Lebacq-Verheyden AM, Coy D et al. cDNA cloning, characterization and brain region-specific expression of a neuromedin-B preferring bombesin receptor. Neuron 1991; 6:421-30.
16. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R et al. BRS-3: novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993;268:5979-84.
17. 13lbombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci U S A 1995; 92:6205-9.
18. Bunnett G. Gastrin-releasing peptide. In: Walsh JH, Dockray GJ, editors. Gut peptides: biochemistry and physiology. New York: Raven Press, Ltd; 1994.p.423-45.
19. Delle Fave G, Annibale B, De Magistris L, Severi C, Bruzzone R, Puoti M et al. Bombesin effects on human GI functions. Peptides 1985;6:113-6.
20. Alexander RW, Upp Jr JR, Poston GJ, Gupta V, Townsend Jr CM, Thompson JC. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res 1988;48:1439-41.
21. Moody TW, Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci 1993;52:1161-73.
22. Wang QJ, Knezetic JA, Schally AV, Pour PM, Adrian TE. Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. Int J Cancer 1996;236:528-34.
23. Kim S, Hu W, Kelly DR, Hellmilch MR, Evers BM, Chung DH. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg 2002;235:621-30.
24. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-20.
25. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999;155: 2067-76.
26. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-9.
27. 2: an in vitro/in vivo structure activity relationship study where x=0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem 2003;14:93-102.
28. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999;99:2235-68.
29. 6]. Polyhedron 1996;15:1079-89.
30. 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med 1999;40:1913-7.
31. 99mTc-labelled neurotensin analogs with optimized biodistribution properties. J Med Chem 2006;49:1833-6.
32. 99mTc(I)-tlicarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjug Chem 2000;11:345-51.
33. García-Garayoa E, Allemann-Tannahill L, Bläuenstein P, Willmann M, Carrel-Rémy N, Tourwé D et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 2001; 28:75-84.
34. 99Tc. Eur J Nucl Med 1982;7:35-6.
35. 99mTc(I)postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug Chem 2002;13:599-604.
36. 125I-Tyr4]bombesin by tumor cells. Prostate 1994;25:29-38.
37. Lin JT, Coy DH, Mantey SA, Jensen RT. Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors. Eur J Pharmacol 1995;294:55-69.
38. Devin C, Bernad N, Cristau M, Artis-Noel A, Heitz A, Fehrentz JA et al. Synthesis and biological evaluation of C-terminal hydroxyamide analogues of bombesin. J Peptide Sci 1999;5:176-84.
39. Mantey S, Frucht H, Coy DH, Jensen RT. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes. Mol Pharmacol 1993;45:762-74.
40. Zhu WY, Goke B, Williams JA. Binding, internalization and processing of bombesin by rat pancreatic acini. Am J Physiol 1991;261:G57-G64.
41. 99mTc(I)labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol 2002;29:553-60.
42. 3. Cancer Res 2003;63:4082-8.
43. 99mTc: a preclinical study. J Med Chem 2005; 48:100-10.
44. 68Ga-labeled bombesin(6-14) analog. J Nucl Med 2005;46:691-9.
45. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006;47:492-501.